Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-228A
- Development stage
- Phase 1
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral (tablet)
01
Overview
AD-228A is an orally administered small molecule drug candidate developed by Addpharma for the treatment of primary hypercholesterolemia. It is classified as an antihyperlipidaemic agent, but its precise mechanism of action has not been defined in public sources. As of March 2025, it is a new molecular entity and has been studied in preclinical and early clinical settings, with planned phase I trials to evaluate its safety and pharmacokinetics compared to coadministration with related compounds (AD-2281 and AD-2282). The drug targets cholesterol management in patients with elevated blood lipid levels[1][2][3].
- Other names
- AD 228AAD228AAD-228A
Beyond the preview
Go deeper on AD-228A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-228A.